Hemophilia is a serious condition that can limit the ability to avoid episodes of bleeding. Treatment includes regular infusions of proteins to replace what the body doesn’t produce naturally ...

Intellia Therapeutics (NASDAQ:NTLA) is opting out of an agreement with Regeneron Pharmaceuticals (NASDAQ:REGN) to co-develop a factor IX gene editing therapy for hemophilia A and B, the ...

(Reuters) - Pfizer said on Thursday it will end global development of its hemophilia gene therapy, Beqvez, citing soft demand ...

NEW YORK/TOKYO -- Pfizer will end global development and commercialization of Beqvez, a gene therapy for hemophilia, after the drugmaker dropped its other similar treatment for the disorder in ...